This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ONS Oncobiologics (ONS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Oncobiologics Stock (NASDAQ:ONS) 30 days 90 days 365 days Advanced Chart Get Oncobiologics alerts:Sign Up Key Stats Today's Range$2.01▼$2.2250-Day Range$0.72▼$7.4052-Week Range$0.57▼$1.53Volume1.59 million shsAverage Volume69,024 shsMarket Capitalization$149.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ. Read More Receive ONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONS Stock News HeadlinesBBC slammed for 'biased' Wimbledon coverage of Marketa Vondrousova vs Ons Jabeur finalAugust 2, 2023 | mirror.co.ukMOns Jabeur ‘kicked off’ Wimbledon centre court moments before women’s finalJuly 30, 2023 | mirror.co.ukMGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.July 12 at 2:00 AM | Investors Alley (Ad)Are Away Carry-Ons Worth the Hype?April 27, 2023 | nytimes.comONS - the Office of National StatisticsOctober 5, 2022 | dailymail.co.ukSee More Headlines ONS Stock Analysis - Frequently Asked Questions When did Oncobiologics IPO? Oncobiologics (ONS) raised $35 million in an initial public offering (IPO) on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager. What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR) and Exelixis (EXEL). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONS Previous SymbolNYSE:ONS CIK1649989 Webwww.oncobiologics.com Phone(609) 619-3990FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.84 million Net Margins-464.47% Pretax MarginN/A Return on EquityN/A Return on Assets-93.28% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual Sales$3.81 million Price / Sales38.28 Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-1.49Miscellaneous Outstanding Shares72,200,000Free FloatN/AMarket Cap$145.84 million OptionableNot Optionable Beta-0.27 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ONS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.